RobertSMannelMD

Clinical Trials

• Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Start of enrollment: 1998 Oct 01

  Completed

  Phase 3

• Paclitaxel in Treating Patients With Ovarian Stromal Cancer Start of enrollment: 2000 Nov 20

  Completed

  Phase 2

• Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Start of enrollment: 2005 Jan 01

  Completed

  Phase 1

• Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21

  Active, not recruiting

  Phase 3

• Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer Start of enrollment: 2006 Jan 01

  Completed

  Phase 2

• Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Start of enrollment: 2007 Sep 01

  Completed

  Phase 1, Phase 2

• Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer Start of enrollment: 2008 Mar 10

  Completed

  Phase 2

• Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes Start of enrollment: 2007 Apr 02

  Completed

• Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25

  Active, not recruiting

  Phase 2

• Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors Start of enrollment: 2007 Oct 09

  Completed

  Phase 2

• Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06

  Active, not recruiting

  Phase 3

• Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer Start of enrollment: 2008 Jan 17

  Completed

  Phase 1

• Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2008 Sep 01

  Completed

  Phase 2

• Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18

  Recruiting

  Phase 3

• Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01

  Completed

  Phase 3

• Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23

  Active, not recruiting

  Phase 3

• OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission Start of enrollment: 2010 Jul 01

  Completed

  Phase 2

• Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 27

  Completed

  Phase 2

• Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 13

  Completed

  Phase 2

• CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells Start of enrollment: 2009 Apr 13

  Active, not recruiting

  Not Applicable

• Collecting Tumor Samples From Patients With Gynecological Tumors Start of enrollment: 1992 Jun 01

  Completed

• YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Start of enrollment: 2007 Sep 01

  Terminated

• Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29

  Active, not recruiting

  Phase 3

• Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2009 Aug 17

  Active, not recruiting

  Phase 3

• Lymphedema After Surgery in Patients With Endometrial Cancer, Cervical Cancer, or Vulvar Cancer Start of enrollment: 2012 Jun 01

  Unknown status

  Not Applicable

• Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Jan 19

  Active, not recruiting

  Not Applicable

• Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Start of enrollment: 2009 Sep 14

  Active, not recruiting

  Phase 2

• Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2009 Oct 28

  Completed

  Phase 1

• Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Start of enrollment: 2009 Nov 01

  Terminated

  Phase 3

• Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Oct 01

  Completed

  Phase 2

• Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors Start of enrollment: 2010 Feb 08

  Active, not recruiting

  Phase 2

• Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Apr 05

  Completed

  Phase 1

• Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Start of enrollment: 2010 Apr 01

  Completed

• Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Start of enrollment: 2010 Oct 12

  Active, not recruiting

  Phase 3

• Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12

  Active, not recruiting

  Phase 3

• EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Nov 01

  Completed

  Phase 2

• Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2010 Jun 01

  Completed

  Phase 2

• Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer Start of enrollment: 2010 Jun 07

  Completed

• Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Start of enrollment: 2010 Aug 01

  Completed

  Phase 2

• Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 06

  Completed

  Phase 2

• Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Start of enrollment: 2011 Jun 06

  Completed

  Phase 2

• Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Start of enrollment: 2010 Nov 01

  Completed

  Phase 2

• Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2011 Oct 01

  Completed

  Phase 2

• Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer Start of enrollment: 2011 May 23

  Completed

  Phase 2

• Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer Start of enrollment: 2011 Apr 04

  Completed

  Phase 2

• Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2011 Mar 14

  Completed

  Phase 1

• Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2011 Mar 01

  Completed

• Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer Start of enrollment: 2011 Apr 04

  Active, not recruiting

  Phase 1

• Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2011 Mar 21

  Completed

  Phase 2

• Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Start of enrollment: 2011 Aug 15

  Active, not recruiting

• Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Start of enrollment: 2011 Apr 12

  Active, not recruiting

• Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09

  Completed

  Phase 3

• Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2011 Oct 11

  Completed

  Phase 1

• Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2011 Dec 12

  Completed

  Phase 2

• EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2012 Jul 09

  Completed

  Phase 1

• Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04

  Terminated

  Phase 3

• Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia Start of enrollment: 2012 Jun 18

  Completed

  Phase 3

• Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva Start of enrollment: 2012 Jul 02

  Active, not recruiting

  Phase 2

• Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer Start of enrollment: 2013 Jun 05

  Active, not recruiting

  Not Applicable

• Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer Start of enrollment: 2012 Oct 01

  Completed

  Phase 1

• Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2013 Sep 30

  Completed

  Phase 1

• Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Start of enrollment: 2014 Feb 14

  Terminated

  Phase 2

• Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17

  Active, not recruiting

  Phase 2, Phase 3

• Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Start of enrollment: 2014 Feb 27

  Active, not recruiting

  Phase 2, Phase 3

• Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Start of enrollment: 2014 Jul 11

  Active, not recruiting

  Phase 2, Phase 3

• Join now to see all